I am Majid Asadi, I am working as a researcher at the Cellular and Molecular Research Center and the Medical Plants Research Center of Shahrekord University of Medical Sciences. I am the Executive Manager of some reputed international journals, and the manager of Nahalgostar Charmahal Co. which is a scientific base company. I am also an associate member of Iranian Society of Biology, the Iranian Society of Plant Physiology, and the Iranian Medicinal Plants Society. I have published more than 30 scientific papers in peer review international journals. I have presented my works in more than 10 national and international congresses. I have one patent on regeneration of Kelussia odoratissima Mozaff. I have studied effects of magnetic fields and other environmental factors on germination and enzyme activities of medicinal plants. I am curious to understand that how medicinal plants could treat the diseases and helping human, to discover new drugs. So, I am interested in evaluating of pharmaceutical effects of medicinal plant on human diseases. Recently I have focused on treatment of cancer by medicinal plants and their phytochemicals.
According to growing incidence of cancer, it seems necessary to develop more novel approaches with higher efficiency so that the disease intensity could be declined. This article is a review of Iran’s medicinal plants which have been already examined for anticancer effects, and also seeks to offer their main compounds and mechanisms of anticancer activities. In order to gather information the words such as medicinal plants, cytotoxicity, anti-cancer, cell line, and plant compounds were searched in online databases such as Web of Science, Scopus, Pubmed, ISC, and SID. In the studies plants such as Ferula assa-foetida, Thymus vulgaris, Thymbra spicata, Taverniera spartea, Peganum harmala, Viola tricolor, Achillea wilhelmsii, Mentha pulegium, Ammi visnaga, Camellia sinensis, Avicennia marina, Silybum marianum, Artemisia absinthium L., Curcuma longa, Crocus sativus L., Zingiber officinale, Olea europae, Taxus baccata L., Nigella sativa, Allium sativum L., Lepidium sativum, Trigonella foenum-graceum L., Glycyrrhiza glabra, Physalis alkekengi, Lagenaria siceraria Standl, Ferula gummosa, Boswellia serrata, Urtica dioica L., Ammi majus, Rosa damascene, Astragalus cystosus, Myrtus communis, Vinca rosea, Citrullus colocynthis, Polygonum aviculare, and Astroudaucus orientalis have been already examined for anticancer effects. Antioxidant activity, cell cycle arrest, induction of apoptosis, and inhibition of angiogenesis were the most mechanisms this plants for its anticancer activities. Vinblastine, vincristine, curcumin, myrtucommulone, taxol, boswellic acids, and umbelliprenin, quercetin, catechin, cucurbitacin, kaempferol, thymol, carvacrol, 1,8-cineole, α-pinene, myrecene, β-sitosterol were some compounds with reported anti-cancer effects in most works. The present study indicated that the Iran's medicinal plants contain the compounds engaging specifically in fighting cancer cells and inhibiting growth and destruction of tumor cells only by affecting cancer cells. Keywords: Medicinal plants, Cancer, Apoptosis, Phytochemicals.
Introduction: There is evidence that suggests patients with type 2 diabetes mellitus and hyperinsulinemia are linked to malignancies. The glycemic control of T2DM involves the widespread use of medications such as metformin, and/or sulfonylureas. The effect of using these medications on the incidence of cancer has not been well studied. Materials and Methods: The meta-analysis involved using PubMed,Randomized Control Trials (RCTs), cohorts, and case–control studies that were published till December 2013. These were used to assess the effects of metformin and/or sulfonylurea on the risk of developing cancer in T2DM patients. Fixed and random effects meta-analysis models were used. Results: Analyzing thirty four studies on metformin in T2DM patients showed that using metformin increased the risk of developing cancer. This was clear in cohort and case-control studies, but the RCTs did not concur. Data from 18 sulfonylurea studies in subjects with T2DM showed that sulfonylurea use is associated with an increase in all-cancer risk in cohort studies, but this was not concurrent with data from RCTs and case-control studies. Conclusions: The analysis, using pooled primary data, showed that using metformin reduces the risk of cancer while sulfonylurea use could be associated with an increased risk of cancer in T2DM patients. These findings however, need to be confirmed with several large-scale RCTs before therapy is altered in the clinical setting.